Future Anti-Adipositus medication such as Wegovy can let the weight melt - But you can also cause unbearable nausea . Now scientists have identified a brain path that is involved in this frequent side effect, which increases the prospect of effective weight loss medication without unpleasant side effects 1 .

The scientists found that the nausea brain circle, which also has a Aversion to food is separated from the circle, which helps the medication to generate the feeling of satiety, Feeling of abundance that prevents people from eating more .

"The implication is that we can now selectively address the saturation circles without addressing the aversion circles. We could potentially develop better medication with fewer side effects," says Amber Alhadeff, a neuroscientist at the Monell Chemical Senses Center in Philadelphia, Pennsylvania and co -author of the study, which is published today in Natur was.

illness and health

medication such as Wegovy ahmen a hormone called glucagon-like peptide 1 (GLP-1), which controls the blood sugar level and acts on the brain to reduce the appetite 2 . (Wegovy and the Ozempic diabetes medication are brand names for Semaglutid , which is made by Novo Nordisk, based in BAGSVærd, Denmark.) Several regions of the brain GLP-1 receptors, but which specific receptor populations are involved in the effects of the medication is not fully understood.

In order to clarify this uncertainty, Alhadeff and her colleagues first killed neurons with GLP-1 receptors in certain brain regions of mice. Then they gave the mice a GLP-1-imitation medication: either Semaglutid or Exenatide, which also has decreasing effects.

mice, which the GLP-1 neurons in a region called brain stem were missing, ate normally. This showed that the effect of the medication had been completely blocked. But the medication still looked after the researchers killed the GLP 1 neurons in the brain region called Hypothalamus, which is important for appetite regulation and was considered to be the effect of GLP-1 medication. "We were shocked," says Alhedeff. "The quintessence is that the brain stem is really the primary place of the effect of the medication."

Then the researchers examined two sub-regions of the brain stem, the Area postrema (AP) and the Nucleus of the Nucleus Solitarius (NTS). When the scientists switched on the AP neurons of the animals, the mice showed nausea and food aversion and reduced their food intake. In contrast, mice whose NTS neurons were activated, the animals returned during food-but showed no signs of nausea.

This means that nausea is not necessary so that GLP-1 medication suppress food intake. This is one of the most important points in the study, says Martin Myers, a neuroscientist at the University of Michigan in Ann Arbor. "If there was a way to only switch on the NTS-GLP 1 receptorneurons or all other GLP 1 receptorneurons, and only to avoid those in the AP, that would certainly be a much better medication," he says. "Of course, the real difficulty is how to do it."